Clinical Trial Update: ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update for SER-109 versus placebo in adults with recurrent Clostridium difficile infection (ECOSPOR III) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• SER-109

Snippet

Sponsor: Seres Therapeutics, Inc. | Conditions: Clostridium Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2023-04-27